Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals

Clinical Infectious Diseases

Volumn 36, Issue 4, 2003, Pages 482-490

  Mondy, Kristin ^a   Yarasheski, Kevin ^a   Powderly, William G ^a   Whyte, Michael ^a   Claxton, Sherry ^a   DeMarco, Debra ^a   Hoffmann, Mary ^a   Tebas, Pablo ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ANTIRETROVIRUS AGENT; CALCIFEDIOL; CALCITRIOL; CALCIUM; CHOLESTEROL; DEOXYPYRIDINOLINE; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE; PROTEINASE INHIBITOR; PYRIDINOLINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TESTOSTERONE; THYROTROPIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; BONE BIOPSY; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BONE MINERALIZATION; BONE TURNOVER; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; RISK FACTOR; SMOKING; STEROID THERAPY; VIRUS LOAD; WEIGHT REDUCTION;

ADULT; BONE AND BONES; BONE DENSITY; BONE DISEASES, METABOLIC; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; PREVALENCE; RISK FACTORS; WEIGHT LOSS;

EID: 0037442930     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/367569     Document Type: Article

References (26)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725-33.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
3. Brinkman K, Hadewych JM, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as a common pathway. AIDS 1998; 12:1735-44.
4. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-8.
5. Miller KD, Cameron M, Wood LV, et al. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med 2000; 133:192-6.
6. Chariot P, Drogou I, de Lacroix-Szmania I, et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol 1999; 30:156-60.
7. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13:F63-70.
8. Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351:871-5.
9. Flynn TE, Bricker LA. Myocardial infarction in HIV-infected men receiving protease inhibitors. Ann Intern Med 1999; 131:548.
10. Lonergan JT, Behling C, Pfander H, et al. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 2000; 31:162-6.
11. Meyer D, Behrens G, Schmidt RE, Stoll M. Osteonecrosis of the femoral head in patients receiving HIV protease inhibitors. AIDS 1999; 13:1147-8.
12. Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000; 14:F63-7.
13. Hoy J, Hudson J, Law M, Cooper DA. Osteopenia in a randomized, multicenter study of protease inhibitor (PI) substitution in patients with the lipodystrophy syndrome and well-controlled HIV viremia [abstract 208]. In: Progam and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco). Washington, DC: Foundation for Retroviruses and Human Health, 2000:114.
14. Negredo E, Gel S, Arisa ER, et al. Bone mineral density (BMD) in HIV-1-infected patients [abstract 626]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Washington, DC: Foundation for Retroviruses and Human Health, 2001:232.
15. Masur H, Miller KD, Jones EC, et al. High prevalence of osteonecrosis of the femoral head in HIV-infected adults. Ann Intern Med 2002; 137:17-25.
16. Knobel H, Guelar A, Valdecillo G, Nogues X, Diez A. Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS 2001; 15:807-8.
17. Wang MWH, Teitelbaum SL, Tebas P, et al. Indinavir inhibits bone formation while ritonavir inhibits osteoclast differentiation and function [abstract 541]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Washington, DC: Foundation for Retroviruses and Human Health, 2001:206.
18. Carr A, Miller J, Eisman JA, Cooper DA. Osteopenia in HIV-infected men: association with asymptomatic lactic acid acidemia and lower weight pre-antiretroviral therapy. AIDS 2001; 15:703-9.
19. Tebas P, Claxton S, DeMarco D, et al. Circulating leptin and lactate levels are not associated with osteopenia in HIV-infected men switched from PI-based to NVP-based HAART [abstract 634]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Washington, DC: Foundation for Retroviruses and Human Health, 2001:234.
20. Monier P, McKown K, Bronze MS. Osteonecrosis complicating highly active antiretroviral therapy in patients infected with human immunodeficiency virus. Clin Infect Dis 2000; 31:1488-92.
21. Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N, Grinspoon S. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 1999; 84:1932-7.
22. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group. World Health Organ Tech Rep Ser 1994; 843:1-129.
23. Mondy K, Claxton S, Hoffman M, et al. Bone histomorphometry in HIV-infected men. In: Proceedings of the 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (Athens), 2001.
24. Bradford-Hill A. The environment and disease: association or causation? President's address. Proc Royal Soc Med 1965; 9:295-300.
25. Wang MWH, Teitelbaum SL, Tebas P, Powderly WG, Ross FP. Indinavir administration leads to bone loss in mice [abstract 713-T]. In: Program and abstracts of the 9th Conference on Retrovirus and Opportunistic Infections (Seattle). Washington, DC: Foundation for Retroviruses and Human Health, 2002:313.
26. 2-vitamin D [abstract]. Antiviral Ther 2000; 5(Suppl 5):19.